Is Venetoclax on the market?

Venetoclax (Venetoclax) is a potent, selective and orally bioavailable small molecule inhibitor of B-cell lymphoma 2 (BCL-2), a novel cancer in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ( SLL) and acute myeloid leukemia (AML), it originally received accelerated approval in the United States in April 2016 for the treatment of adult patients with CLL who have a 17p deletion and have received at least one prior therapy, sold under the trade name Venclexta and commonly known as venetoclax.

In December 2016, the European Medicines Agency (EMA) concluded that the benefits of venetoclax outweighed its risks and that it could be authorized for use in the EU, marketed under the trade name Venclyxto. Although there is a risk of tumor lysis syndrome, a complication that occurs when cancer cells are destroyed too quickly, this risk can be controlled through preventive measures, such as gradually increasing or reducing the dose when needed. Venacla has been approved by the State Food and Drug Administration for marketing in China in 2020, and will be included in the Class B medical insurance directory through the regulations of the National Medical Insurance Administration in 2023. The trade name is Venecola.

The original drug Venetacla , specifications 100mg*14 tablets per box, which is marketed in China, may cost around 5,000 yuan per box. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).